CoChat

Antibodies to a Full-Length VAR2CSA Immunogen Are Broadly Strain-Transcendent but Do Not Cross-Inhibit Different Placental-Type Parasite Isolates

Open access

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Abstract

The high molecular weight, multidomain VAR2CSA protein mediating adhesion of Plasmodium falciparum-infected erythrocytes in the placenta is the leading candidate for a pregnancy malaria vaccine. However, it has been difficult so far to generate strong and consistent adhesion blocking antibody responses against most single-domain VAR2CSA immunogens. Recent advances in expression of the full-length recombinant protein showed it binds with much greater specificity and affinity to chondroitin sulphate A (CSA) than individual VAR2CSA domains. This raises the possibility that a specific CSA binding pocket(s) is formed in the full length antigen and could be an important target for vaccine development. In this study, we compared the immunogenicity of a full-length VAR2CSA recombinant protein containing all six Duffy binding-like (DBL) domains to that of a three-domain construct (DBL4-6) in mice and rabbits. Animals immunized with either immunogen acquired antibodies reacting with several VAR2CSA individual domains by ELISA, but antibody responses against the highly conserved DBL4 domain were weaker in animals immunized with full-length DBL1-6 recombinant protein compared to DBL4-6 recombinant protein. Both immunogens induced cross-reactive antibodies to several heterologous CSA-binding parasite lines expressing different VAR2CSA orthologues. However, antibodies that inhibited adhesion of parasites to CSA were only elicited in rabbits immunized with full-length immunogen and inhibition was restricted to the homologous CSA-binding parasite. These findings demonstrate that partial and full-length VAR2CSA immunogens induce cross-reactive antibodies, but inhibitory antibody responses to full-length immunogen were highly allele-specific and variable between animal species.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0016622

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Immunization with DBL4-6 and DBL1-6 VAR2CSA recombinant proteins induces antibodies which target multiple domains in VAR2CSA. Mouse and rabbit plasma were screened by ELISA against different VAR2CSA recombinant proteins. (A) Rabbit and mouse plasma against the full-length DBL1-6 recombinant protein were screened against individual VAR2CSA domains, (B) rabbit and mouse plasma against DBL4-6 recombinant protein were screened against individual VAR2CSA domains. The end point titration of the corresponding preimmune plasma in ELISA ranged from 0 to 200 at OD 0.1. R1, rabbit #1; R2, rabbit #2; M1, mouse #1; M2, mouse 2; M3, mouse #3.
Figure 1 Immunization with DBL4-6 and DBL1-6 VAR2CSA recombinant proteins induces antibodies which target multiple domains in VAR2CSA. Mouse and rabbit plasma were screened by ELISA against different VAR2CSA recombinant proteins. (A) Rabbit and mouse plasma against the full-length DBL1-6 recombinant protein were screened against individual VAR2CSA domains, (B) rabbit and mouse plasma against DBL4-6 recombinant protein were screened against individual VAR2CSA domains. The end point titration of the corresponding preimmune plasma in ELISA ranged from 0 to 200 at OD 0.1. R1, rabbit #1; R2, rabbit #2; M1, mouse #1; M2, mouse 2; M3, mouse #3.CC BY · PubMed Central
Figure 2 Immunization with DBL4-6 and DBL1-6 VAR2CSA recombinant proteins induces antibodies against the surface of IEs-CSA. Fluorescence of IEs labeled by rabbit plasma raised against 3D7 DBL1-6 (A) or 3D7 DBL4-6 (B) or mouse plasma raised against 3D7 DBL1-6 (C) or 3D7 DBL4-6 (D) is shown compared to the corresponding preimmune plasma (shaded histograms). In (A) and (B), blue histograms represent labeling with polyclonal plasma, green histograms show the corresponding purified IgG. In (C) and (D), individual mouse plasma were tested; blue (mouse 1), green (mouse 2), and orange (mouse 3).
Figure 2 Immunization with DBL4-6 and DBL1-6 VAR2CSA recombinant proteins induces antibodies against the surface of IEs-CSA. Fluorescence of IEs labeled by rabbit plasma raised against 3D7 DBL1-6 (A) or 3D7 DBL4-6 (B) or mouse plasma raised against 3D7 DBL1-6 (C) or 3D7 DBL4-6 (D) is shown compared to the corresponding preimmune plasma (shaded histograms). In (A) and (B), blue histograms represent labeling with polyclonal plasma, green histograms show the corresponding purified IgG. In (C) and (D), individual mouse plasma were tested; blue (mouse 1), green (mouse 2), and orange (mouse 3).CC BY · PubMed Central
Figure 3 Antibodies against the full length protein inhibit 3D7 DBL1-6 VAR2CSA recombinant protein binding to CSA-containing proteoglycans. Purified antibodies were assessed for their capacity to inhibit protein binding to the CSA-containing proteoglycan decorin. Protein A purified rabbit IgG were preincubated at different concentrations with full-length recombinant VAR2CSA protein prior to addition to wells containing the CSA-containing proteoglycan decorin. Percent inhibition was calculated relative to the corresponding control protein A purified IgG raised against varO NTS-DBL1 domain. R1, rabbit #1; R2, rabbit #2.
Figure 3 Antibodies against the full length protein inhibit 3D7 DBL1-6 VAR2CSA recombinant protein binding to CSA-containing proteoglycans. Purified antibodies were assessed for their capacity to inhibit protein binding to the CSA-containing proteoglycan decorin. Protein A purified rabbit IgG were preincubated at different concentrations with full-length recombinant VAR2CSA protein prior to addition to wells containing the CSA-containing proteoglycan decorin. Percent inhibition was calculated relative to the corresponding control protein A purified IgG raised against varO NTS-DBL1 domain. R1, rabbit #1; R2, rabbit #2.CC BY · PubMed Central
Figure 4 Immunization with DBL1-6 VAR2CSA recombinant protein induces strain-specific adhesion blocking antibodies. (A) Adhesion blocking properties of individual mouse plasma (1∶5 dilution) or pooled mouse plasma (1∶5 dilution) were tested against the 3D7csa and 7G8csa parasite lines. (B) Adhesion blocking properties of immune plasma (1∶5 dilution) or purified IgG (0.5 mg/ml) from rabbit #1 immunized with the DBL4-6 (grey bars) or DBL1-6 recombinant proteins (black bars) were tested against several different CSA-binding parasite lines and two CD36-binding negative control parasite lines. (C) Dose-dependency adhesion inhibition properties of rabbit #2 anti-3D7 DBL1-6 plasma and purified IgG tested against 3D7csa parasites. Rabbit #2 anti-3D7 DBL1-6 plasma (1∶5 dilution) and purified IgG (0.5 mg/ml) adhesion blocking properties were tested on four heterologous CSA-binding parasite lines and a CD36-binding negative control parasite line. For antibody adhesion inhibition, CSA-binding parasite lines were tested for adhesion to CSA and CD36 binding parasite lines were tested for adhesion to CD36. Percent inhibition was calculated relative to the corresponding preimmune rabbit plasma/purified IgG or a pool of three preimmune mouse plasma. Adhesion inhibition is the mean of 4 independent spots for all assays.
Figure 4 Immunization with DBL1-6 VAR2CSA recombinant protein induces strain-specific adhesion blocking antibodies. (A) Adhesion blocking properties of individual mouse plasma (1∶5 dilution) or pooled mouse plasma (1∶5 dilution) were tested against the 3D7csa and 7G8csa parasite lines. (B) Adhesion blocking properties of immune plasma (1∶5 dilution) or purified IgG (0.5 mg/ml) from rabbit #1 immunized with the DBL4-6 (grey bars) or DBL1-6 recombinant proteins (black bars) were tested against several different CSA-binding parasite lines and two CD36-binding negative control parasite lines. (C) Dose-dependency adhesion inhibition properties of rabbit #2 anti-3D7 DBL1-6 plasma and purified IgG tested against 3D7csa parasites. Rabbit #2 anti-3D7 DBL1-6 plasma (1∶5 dilution) and purified IgG (0.5 mg/ml) adhesion blocking properties were tested on four heterologous CSA-binding parasite lines and a CD36-binding negative control parasite line. For antibody adhesion inhibition, CSA-binding parasite lines were tested for adhesion to CSA and CD36 binding parasite lines were tested for adhesion to CD36. Percent inhibition was calculated relative to the corresponding preimmune rabbit plasma/purified IgG or a pool of three preimmune mouse plasma. Adhesion inhibition is the mean of 4 independent spots for all assays.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 43

Metadata

Authors
Avril, M., Hathaway, M. J., Srivastava, A., Dechavanne, S., Hommel, M., Beeson, J. G., Smith, J. D., & Gamain, B.
Affiliations
  • Center for Infectious Disease Research (US)
  • Centre National de la Recherche Scientifique (FR)
  • Walter and Eliza Hall Institute of Medical Research (AU)
Corresponding author
  • Smith, Joseph D.
  • Gamain, Benoît
Venue
PLoS ONE
Published
2011-02-07
Volume
6
Issue
2
Pages
e16622
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2023380419
Cited by
40
References
54
Citations by year
2024: 1 · 2022: 3 · 2021: 3 · 2020: 2 · 2019: 3 · 2018: 1 · 2017: 3 · 2016: 2 · 2015: 5 · 2014: 2 · 2013: 3 · 2012: 7
FWCI
5.35
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Bill and Melinda Gates Foundation
  • Sanofi
  • European Commission (201222)
  • Medical Research Council (FP7/20072013)
  • Australian Research Council
  • National Health and Medical Research Council
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Health Sciences › Medicine › Hematology › Blood groups and transfusion
  • Life Sciences › Immunology and Microbiology › Parasitology › Vector-borne infectious diseases
Keywords
VAR2CSA, Plasmodium falciparum, placental adhesions, chondroitin sulfate A, Duffy binding-like domain, cross-reactive antibodies, adhesion inhibition, vaccine candidate
MeSH terms
Amino Acid Sequence, Animals, Antibodies, Protozoan, Antibody Specificity, Antigens, Protozoan, Cells, Cultured, Cross Reactions, Female, Humans, Immunization, Mice, Inbred BALB C, Placenta, Pregnancy, Rabbits, Species Specificity, Pregnancy Complications, Parasitic, Malaria, Falciparum, Malaria Vaccines, Protein Isoforms, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.